graph Evidence gap map comparisons
ipilimumab based treatmentipilimumab aloneipilimumab based treatmentnivolumab based treatmentpembrolizumab alonepembrolizumab based treatment
ipilimumab alone Ipilimumab (10 mg/kg) ipilimumab plus gp100 ipilimumab plus SoC nivolumab alone pembrolizumab (10mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (2mg/kg) pembrolizumab plus SoC
mML - 2nd line (L2)
mML - L2 - all population 11                    
mML - L2 - BRAF mutant 1   
Comparator:  vs ipilimumab alone;   vs gp100;   vs placebo plus SoC;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;